NATCO launches anticoagulant drug Rivaroxaban in India
Hyderabad: Natco Pharma Limited has recently announced the launch of Rivaroxaban molecule, under brand RPIGAT.
Rivaroxaban is an anticoagulant medication used to treat and prevent blood clots.
Rivaroxaban is currently sold by Bayer under brand name of Xarelto, in the Indian market.
"After successful previous launches of DABIGAT (Dabigatran) and APIGAT (Apixaban) by NATCO, this latest Rivaroxaban NOAC (Novel oral anti-coagulant) is in line with our Company's mission of affordable medicines accessible to all," the release stated.
NATCO has launched RPIGAT in four strengths- 20 mg, 15 mg, 10 mg and 2.5 mg. The 20 mg strength is priced at an MRP of INR 14.0 per tablet.
Read also: Natco Pharma Pomalidomide capsules get USFDA okay
The Company has seven manufacturing facilities spread across India with modern research laboratories, capabilities in New Drug Development, etc.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.